

01-11-01

09/743674  
525 Rec'd PCT/PTO 10 JAN 2001

FORM PTO-1390 (REV. 3-90)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEYS DOCKET NO.  15-840	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)</b>					
INTERNATIONAL APPLICATION NO. PCT/GB99/02205		INTERNATIONAL FILING DATE 9 July 1999 (09.07.99)		PRIORITY DATE CLAIMED 10 July 1998 (10.07.98)	
TITLE OF INVENTION <b>SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES AGAINST PATHOGENIC NEISSERIA</b>					
APPLICANT(S) FOR DO/EO/US <b>ALA'ALDEEN, Dlawer and TODD, Ian</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items under 35 U.S.C. 371: 1. This express request to immediately begin national examination procedures (35 U.S.C. 371(f)). 2. The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees as follows:					
CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS	71 - 20 =	51	x \$18.00	= \$918
	INDEPENDENT CLAIMS	16 - 3 =	13	x \$80.00	= \$1040
	MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270.00	
	BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)):				
	<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482)				
	.....\$890.00				
	<input type="checkbox"/> No International preliminary examination fee paid to USPTO (37 CFR 1.482) but International search fee paid to USPTO (37 CFR 1.445 (a)(2)).....				\$710.00
	<input checked="" type="checkbox"/> Neither International preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO.....				\$1000.00
	<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provision of PCT Article 33(2) to 4).....				\$100.00
	<input type="checkbox"/> International search fee prepared by EPO (37 CFR 1.492(a)(5)).....				\$860.00
	Surcharge of \$130.00 for furnishing the National fee or oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(e)).				\$1000
	TOTAL OF ABOVE CALCULATIONS				= \$2958
	Reduction by 1/2 for filing by small entity, if applicable. Applicant qualifies as a small entity under 37 C.F.R. § 1.27.				\$1479
	SUBTOTAL				= \$1479
	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(f)).				
	TOTAL NATIONAL FEE				\$ 1479
	Fee for recording the enclosed assignment (37 CFR 1.21(h)) \$40.00				\$
	TOTAL FEES ENCLOSED				\$1479
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1479</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0630</u>.</p>					

Express Mail No. 8239152096045  
 hereby certify that this paper is being deposited with the  
 U.S. Postal Service as Express Mail addressed to the  
 Assistant Commissioner for Patents, Washington, D.C. 20540

1/10/01  
Gordon M. Bezzel

ATTORNEY'S DOCKET NUMBER  
15-840

3. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
- ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
  - ☒ has been transmitted by the International Bureau.
4. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
5. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
- ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - ☐ have been transmitted by the International Bureau.
6. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
7. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) is enclosed.
8. ☐ A translation of the Annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Other document(s) or information included:

9. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
10. ☐ An assignment document for recording.

Please mail the recorded assignment document to:

- ☐ the person whose signature, name & address appears at the bottom of this page.
- ☐ the following:

11. The above checked items are being transmitted:

- ☐ before the 18th month publication.
  - ☐ after publication and the Article 20 communication but before 20 months from the priority date.
  - ☐ after 20 months but before 22 months (surcharge and/or processing fee included)
  - ☐ after 22 months (surcharge and/or processing fee included)
- Note: Petition to revive (37 CFR 1.137(a) or (b)) is necessary if 35 U.S.C. 371 requirements submitted after 22 months and no proper demand for International Preliminary Examination was made by 19 months from the earliest claimed priority date.
- ☒ by 30 months and a proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
  - ☐ after 30 months but before 32 months and a proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date (surcharge and/or processing fee included.)
  - ☐ after 32 months (surcharge and/or processing fee included).

Note: Petition to revive (37 CFR 1.137(a) or (b)) is necessary if 35 U.S.C. 371 requirements submitted after 32 months and a proper demand for International Preliminary Examination was made by 19 months from the earliest claimed priority date.

12. At the time of transmittal, the time limit for amending claims under Article 19

- ☐ has expired
- ☐ has not yet expired.

13. ☐ Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on \_\_\_\_\_, namely:

14. ☒ Enclosed is an Amendment Before Office Action.

15. ☒ Applicant qualifies as a small entity under 37 C.F.R. §127.

RICHARD A. SHARPE

NAME

WATTS, HOFFMANN, FISHER &amp; HEINKE CO., L.P.A.

P.O. Box 99839

Cleveland, Ohio 44199-0839

SIGNATURE

34,722  
REGISTRATION NO.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

ALA'ALDEEN, Dlawer and TODD, Ian

Serial No.: N/A

Art Unit: not yet assigned

Filed: Herewith

Examiner: N/A

For: SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES  
AGAINST PATHOGENIC NEISSERIA

Docket: 15-840

Watts, Hoffmann, Fisher & Heinke Co., L.P.A.  
PO Box 99839  
Cleveland, Ohio 44199-0839

Box Patent Application  
Assistant Commissioner of Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sirs:

IN THE CLAIMS

Claim 3, line 1, change "any preceding claim" to --claim 1--.

4. (amended) A method as claimed in claim [3] 1, characterized in that the peripheral blood is obtained from naturally infected patients at different stages of illness and the stages include an acute stage (on admission), early convalescence (seven days after admission), late convalescence (six weeks after discharge) and after full recovery (3 months and twelve months after discharge).

Claim 5, line 1, change "any preceding claim" to --claim 1--.

Express Mail Label No. EL39152096045  
I hereby certify that this paper is being deposited with the  
U. S. Postal Service as Express Mail addressed to the  
Assistant Commissioner for Patents, Washington, D.C. 20231  
on 1/10/01  
Ellen M. Gyzels

Claim 6, line 1, change "any preceding claim" to --claim 1--.

Claim 7, line 1, change "any preceding claim" to --claim 1--.

Claim 8, line 1, change "any preceding claim" to --claim 1--.

9. (amended) A method as claimed in claim [8] 1, characterized in that the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period and wherein the predetermined period is 3-10 days and may be 5 days.

10. (amended) A method as claimed in claim [8 or 9] 1, characterized in that the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period and wherein the IL-2 stimulates the proliferation of the activated T-cell lines and clones.

11. (amended) A method as claimed in claim [10] 1, characterized in that the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period and wherein the IL-2 stimulates the proliferation of the activated T-cell lines and clones and said T-cell lines and clones are maintained by weekly stimulation.

12. (amended) A method as claimed in claim [10 or claim 11] 1, characterized in that the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period and wherein the IL-2 stimulates the proliferation of the activated T-cell lines and clones and said stimulation is provided by proteins in the presence of IL-2 and feeder cells.

13. (amended) A method as claimed in claim [12] 1, characterized in that the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period and wherein the IL-2 stimulates the proliferation of the activated

T-cell lines and clones and said stimulation is provided by proteins in the presence of IL-2 and feeder cells and said feeder cells are antigen presenting feeder cells and may be autologous Epstein-Barr virus transformed B-lymphocytes (EBVB).

Claim 14, line 1 change "any preceding claim" to --claim 1--.

15. (amended) A method as claimed in claim [14] 1, characterized in that the specificity of the T-cell lines and clones to neisserial proteins is tested prior to storing for example in liquid nitrogen and the specificity is tested by measurement of tritiated thymidine incorporation in response to stimulation with neisserial proteins compared to irrelevant antigens.

16. (amended) A method as claimed in claim [14] 1, characterized in that [an] the specificity of the T-cell lines and clones to neisserial proteins is tested prior to storing for example in liquid nitrogen and the specificity is tested by measurement of tritiated thymidine incorporation in response to stimulation with neisserial proteins compared to irrelevant antigens and wherein said irrelevant antigen is tetanus toxoid.

Claim 17, line 1, change "any preceding claim" to --claim 1--, and after "that" change "the" to --a--;

line 2, delete "also".

18. (amended) A method as claimed in claim [17] 1, characterized in that the phenotype of the T-cell lines and clones are assessed using flow cytometry and specific monoclonal antibodies wherein the antibodies are CD4<sup>+</sup>, CD8<sup>-</sup> and  $\alpha/\beta$ - and  $\gamma/\delta$ - T-cell receptor (TCR) specific monoclonal antibodies.

Claim 19, line 4, delete "generated according to the method as claimed in any of the preceding claims".

Claim 21, line 1, delete "or 20".

Claim 22, line 1, change "21" to --19--.

Claim 23, line 1, change "any of claim 19 to 22" to --claim 19--.

24. (amended) A method as claimed in claim [23] 19, characterized in that polyclonal antibodies are raised to the T-cell stimulating fraction proteins and the antibodies are used to screen a genomic meningococcal and/or gonococcal expression library.

25. (amended) A method as claimed in claim [24] 19, characterized in that polyclonal antibodies are raised to the T-cell stimulating fraction proteins and the antibodies are used to screen a genomic meningococcal and/or gonococcal expression library and wherein the expression library is a  $\lambda$ ZapII library.

26. (amended) A method as claimed in claim [24 or claim 25] 19, characterized in that polyclonal antibodies are raised to the T-cell stimulating fraction proteins and isolated neisserial polypeptides which react with the antibodies and their respective DNA fragments are further characterized and sequenced.

Claim 28, line 3, delete "generated according to the method of any of claims 1 to 18".

Claim 29, line 1, delete "or claim 28".

30. (amended) A method according to claim [29] 27, characterized in that the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a strain of *Neisseria meningitidis* or a strain of *Neisseria gonorrhoea* and a representative pool of recombinant pBluescript SKII plasmid are excised from the phage library and transformed into *E. coli* strain XL1-Blue.

31. (amended) A method according to claim [30] 27, characterized in that the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a strain of *Neisseria meningitidis* or a strain of *Neisseria gonorrhoea* and a representative pool of recombinant pBluescript SKII plasmid are excised from the phage library and transformed into *E. coli* strain XL1-Blue and the plasmids are excised into XL1-Blue using a helper phage.

32. (amended) A method according to claim [30 or claim 31] 27, characterized in that the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a strain of *Neisseria meningitidis* or a strain of *Neisseria gonorrhoea* and a representative pool of recombinant pBluescript SKII plasmid are excised from the phage library and transformed into *E. coli* strain XL1-Blue and the transformed *E. coli* are cultured in a medium which may contain ampicillin.

Claim 33, line 1, change "any of claims 27 to 32" to --claim 27--.

Claim 34, line 1, change "any of claims 27 to 33" to --claim 27--.

Claim 35, line 1, change "any of claims 27 to 34" to --claim 27--.

Claim 36, line 1, change "any of claims 27 to 35" to --claim 27--.

37. (amended) A method as claimed in claim [36] 27, characterized in that CD4<sup>+</sup> T-cell stimulating bacterial cultures are identified and subcultured and the subcultures are [preferably] rescreened for T-cell stimulation.

38. (amended) A method as claimed in claim [36 or claim 37] 27, characterized in that CD4<sup>+</sup> T-cell stimulating bacterial cultures are identified and subcultured and the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and are further characterized.

Claim 39, line 1 change "any of claims 27 or 28" to --claim 27--.

Claim 41, line 3, delete "generated according to the method as claimed in any of claims 1 to 18".

Claim 42, line 1, change "any of claims 39 to 41" to --claim 40--.

43. (amended) A method as claimed in claim [42] 40, characterized in that the genomic phage display library (PDL) is generated by fragmenting bacterial DNA, cloning and packaging into bacteriophage vectors wherein two vectors are used.

44. (amended) A method as claimed in claim [43] 40, characterized in that the genomic phage display library (PDL) is generated by fragmenting bacterial DNA, cloning and packaging into bacteriophage vectors wherein two vectors are used and the first vector displays peptides up to 1200 amino acids which are expressed at low copy numbers.

45. (amended) A method as claimed in claim [43 or claim 44] 40, characterized in that the genomic phage display library (PDL) is generated by fragmenting bacterial DNA, cloning and packaging into bacteriophage vectors wherein two vectors are used and wherein one [second] vector [preferably] displays up to 415 copies of a peptide up to 50 amino acids in size.

Claim 46, line 1, change "any of claims 40 to 45" to --claim 40--.

Claim 47, line 1, change "any of claims 40 to 46" to --claim 40--.

Claim 48, line 1, change "any of claims 40 to 47" to --claim 40--.

49. (amended) A method as claimed in claim [48] 40, characterized in that CD4<sup>+</sup> T-cell stimulating PDL cultures are identified and subcultured and the subcultures are rescreened for T-cell stimulation.

Claim 50, line 1, change "any of claims 40 to 49" to --claim 40--.



Claim 51, line 2, delete "in";

line 3, delete "accordance with any of claims 27 to 39".

53. (amended) A method as claimed in claim [52] 51, characterized in that the meningococcal or gonococcal genomic lambda phage display library is constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same into a predigested vector, and plating by infecting *E. coli* wherein the vector is a lambda phage.

54. (amended) A method as claimed in claim [53] 51, characterized in that the meningococcal or gonococcal genomic lambda phage display library is constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same into a predigested vector, and plating by infecting *E. coli* wherein the vector is  $\lambda$ pRH825 vector.

55. (amended) A method as claimed in claim [53 or 54] 51, characterized in that the meningococcal or gonococcal genomic lambda phage display library is constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same into a predigested vector, and plating by infecting *E. coli* and the amplified and digested DNA fragments are packaged into the lambda phage using a lambda phage packaging kit.

56. (amended) A method as claimed [any of claims 52 or 55] 51, characterized in that the meningococcal or gonococcal genomic lambda phage display library is constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same into a predigested vector, and plating by infecting *E. coli* and the restriction sites are SpeI or NotI.

57. (amended) A method as claimed in [any of claims 51 to 56] 51, characterized in that the meningococcal or gonococcal genomic lambda phage display library is constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same into a predigested vector, and plating by infecting *E. coli* and the DNA inserts in the plaques formed are sequenced, thereby confirming that the plaques contain DNA fragments of meningococcal or gonococcal origin.


Please cancel claims 72-79 without prejudice or disclaimer of the subject matter thereof.

#### REMARKS

The claims have been amended to eliminate numerous multiple dependencies and to generally put them in a form conducive to prosecution in the United States. Favorable consideration of this application is respectfully requested.

Dated: January 10, 2001

Respectfully submitted,

  
Richard A. Sharpe  
Reg.No. 34,722

Telephone: (216) 241-6700  
Facsimile: (216)241-8151

SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES  
AGAINST PATHOGENIC NEISSERIA

The present invention relates to vaccines for Pathogenic *Neisseria*, and particularly but not exclusively to a screening system for the identification of CD4<sup>+</sup> T-cell stimulating vaccines in Pathogenic *Neisseria*.

The term "vaccine candidates" is used to refer to peptides which may prove, upon further study, to exhibit some form of vaccine property. In particular, the vaccine candidates discussed below are peptides which stimulate CD4<sup>+</sup> T-cells (T-cells with CD4 marker on them).

The generic name Pathogenic *Neisseria* covers the pathogenic organisms *Neisseria meningitidis* and *Neisseria gonorrhoea*.

*Neisseria meningitidis* (the meningococcus) causes meningitis and overwhelming septicaemia that can kill within hours. It also causes outbreaks of meningococcal disease. *Neisseria gonorrhoea* (the gonococcus) causes gonorrhoea and other invasive diseases, e.g. pelvic inflammatory diseases and septic arthritis.

Although the two neisserial species (*N. meningitidis* and *N. gonorrhoea*) have evolved to colonise and invade different anatomical sites of the human body, they are strongly related and share extensive amount of genetic, immunochemical and other biological properties. They are believed to have evolved from a common ancestor, a view strongly supported by the recently released respective genomic sequence data. The outer membrane structure of the two organisms are very similar with a vast number of outer membrane proteins, including some vaccine candidates, being virtually identical. Recent data suggest that vaccines based on conserved (cross-reactive) immunogenic proteins may protect against both organisms.

The mechanisms responsible for the development of natural immunity

09/743674-011001

to meningococcal disease remain unclear and the currently available capsular polysaccharide (CPS)-based vaccines provide only serogroup-specific and short-lived protection and are not effective in children under two years of age. Additionally, the CPS of serogroup B meningococci, which are responsible for the majority of cases in Europe and America, is only very poorly immunogenic in humans, generating mainly IgM antibodies.

Recovery from meningococcal infection is followed by long lasting immunity and, in the absence of immunodeficiencies, second episodes of meningitis (with homologous or heterologous strains) are extremely rare. This fact indicates that there are non-capsular (cross-reactive) antigens that can stimulate T-cell memory and thus generate a long-lasting and cross-protective immunity.

To achieve an efficient humoral immune response resulting in the production of high affinity IgG antibodies and the generation of memory B lymphocytes (B-cells), help from T lymphocytes (T-cells) is required. However, helper T-cells respond to peptide antigens associated with class II molecules of the major histocompatibility complex (MHC - designated HLA in humans) on the surface of antigen presenting cells. Therefore, they will not be stimulated by purified polysaccharide vaccines (T-cell independent B-cell immunogens). To trigger a strong memory T-cell response when the host confronts the virulent organism, the target B-cell epitope should be expressed along with helper T-cell stimulating epitopes. Identification and characterisation of the peptide epitopes that can best stimulate meningococcal specific CD4<sup>+</sup> T-cells is an important part of the present invention. An ideal meningococcal vaccine must consist of a carefully selected mixture of well-characterised B- and T-cell antigens capable of generating a long lasting immunity.

It appears that meningococcal vaccine candidates will also have the potential to protect against gonococcal disease.

In the following description the term T-cell clone is defined as the

population of cells which originate from a single T cell.

In a first aspect, the present invention provides a method of generating T-cell lines and clones specific to neisserial proteins, the method comprising isolating peripheral blood mononuclear cells (PBMCs) from the peripheral blood of normal donors and patients recovering from neisserial disease, culturing the PBMCs with neisserial proteins with or without a proliferation stimulant for a prescribed period, stimulating proliferation of T-cell lines and clones which are specific to neisserial proteins, and maintaining same by regular stimulation.

The neisserial proteins are preferably prepared from *Neisseria meningitidis* and/or *Neisseria gonorrhoea* grown under iron restrictions to induce the expression of iron-regulated proteins.

The peripheral blood is preferably obtained from naturally infected patients at different stages of illness. Preferably the stages include an acute stage (on admission), early convalescence (seven days after admission), late convalescence (six weeks after discharge) and after full recovery (3 months and twelve months after discharge).

Preferably the peripheral blood is heparinised or treated with EDTA and the PBMCs may be isolated therefrom by centrifugation.

Preferably the PBMCs are initially cultured in medium containing human serum. Preferably the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period. Preferably the predetermined period is 3-10 days and may be 5 days.

Preferably IL-2 stimulates the proliferation of the activated T-cell lines and clones. Preferably the T-cell lines and clones are maintained by weekly stimulation. The stimulation may be provided by proteins in the presence of IL-2 and feeder cells. Preferably the feeder cells are antigen presenting feeder cells and may be autologous Epstein-Barr virus transformed B-lymphocytes

(EBVB).

The specificity of the T-cell lines and clones to neisserial proteins is preferably tested prior to storing for example in liquid nitrogen. Preferably the specificity is tested by measurement of tritiated thymidine incorporation in response to stimulation with neisserial proteins compared to irrelevant antigens. Such an irrelevant antigen may be tetanus toxoid. The phenotypes of the T-cell lines and clones are preferably also assessed using flow cytometry and specific monoclonal antibodies. The antibodies are preferably CD4<sup>+</sup>, CD8<sup>-</sup> and  $\alpha/\beta$ - and  $\gamma/\delta$ - T-cell receptor (TCR) specific monoclonal antibodies.

In a second aspect the present invention provides a method of detecting CD4<sup>+</sup> T-cell stimulating proteins, the method comprising fractionating neisserial proteins and testing the ability of said proteins to stimulate proliferation of T-cell lines and clones.

Preferably the T-cell lines and clones are *Neisseria* specific T-cell lines and clones generated according to the method of the first aspect of the invention, as set out above.

The proteins may be fractionated by SDS-PAGE. The fractions are preferably tested for their ability to stimulate the individual T-cell lines and clones. Preferably fractions containing T-cell stimulants are further characterised by SDS-PAGE.

Polyclonal antibodies may be raised to the T-cell stimulating fraction proteins. The antibodies are preferably used to screen a genomic meningococcal and/or gonococcal expression library. Preferably the expression library is a  $\lambda$ ZapII library. Isolated neisserial polypeptides which react with the antibodies and their respective DNA fragments are preferably further characterised and sequenced.

In a third aspect, the present invention provides a method of detecting

CD4<sup>+</sup> T-cell stimulating recombinant proteins, the method comprising screening a genomic meningococcal or gonococcal expression library for recombinant proteins which stimulate T-cell lines and clones.

Preferably the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method of the first aspect of the invention, as set out above.

Preferably the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a strain of *Neisseria meningitidis* or a strain of *Neisseria gonorrhoea*. Preferably a representative pool of recombinant pBluescript SKII plasmid are excised from the phage library and transformed into *E.coli* strain XL1-Blue. Preferably the plasmids are excised into XL1-Blue using a helper phage.

The transformed *E.coli* are preferably cultured in a medium which may contain ampicillin. Meningococcal or gonococcal protein expression is preferably induced by isopropyl-b-D-thio-galactoside.

Preferably the bacteria are heat-killed and sonicated before adding to antigen presenting cells. The expressed proteins are preferably tested for their ability to stimulate the individual T-cell lines and clones. Preferably CD4<sup>+</sup> T-cell stimulating bacterial cultures are identified and subcultured. The subcultures are preferably rescreened for T-cell stimulation.

Preferably the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and may be further characterised.

Alternatively the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a meningococcal or gonococcal genomic lambda phage display library.

In a fourth aspect the present invention provides a method of detecting

CD4<sup>+</sup> T-cell stimulating peptides, the method comprising screening meningococcal or gonococcal genomic phage display libraries (PDLs) to identify peptides which stimulate T-cell lines and clones.

Preferably the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method of the first aspect of the invention, as set out above.

Preferably the genomic phage display library (PDL) is generated by fragmenting bacterial DNA, cloning and packaging into bacteriophage vectors. Preferably two vectors are used. The first vector preferably displays peptides up to 1200 amino acids which are expressed at low copy numbers. The second vector preferably displays up to 415 copies of a peptide up to 50 amino acids in size.

Preferably the PDLs are amplified in respective *E.coli* hosts. The cells are preferably heat killed before testing for the ability of the peptides to stimulate the T-cell lines and clones.

Preferably CD4<sup>+</sup> T-cell stimulating PDL cultures are identified and subcultured. The subcultures are preferably rescreened for T-cell stimulation.

Preferably the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and may be further characterised.

In a fifth aspect the present invention provides a method of detecting CD4<sup>+</sup> T-cell stimulating recombinant proteins, using a meningococcal or gonococcal genomic lambda phage display library in accordance with the third aspect of the invention, as set out above.

The meningococcal or gonococcal genomic lambda phage display library is preferably constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same

00443574-011004  
T00TFO "429ET460



into a pre-digested vector, and plating by infecting *E.coli*.

Preferably the vector is a lambda phage and is preferably  $\lambda$ prH825 vector. The amplified and digested DNA fragments are preferably packaged into the lambda phage using a lambda phage packaging kit. Preferably the restriction sites are *SpeI* or *NotI*.

Preferably the DNA inserts in the plaques formed are sequenced, thereby confirming that the plaques contain DNA fragments of meningococcal or gonococcal origin.

In a sixth aspect the present invention provides the use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2 or an active derivative thereof.

Preferably the polypeptide is a CD4<sup>+</sup> T-cell stimulant.

In a seventh aspect of the present invention there is provided a DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease, the construct comprising a sequence as shown in SEQIDNO3 or an active derivative thereof.

In an eighth aspect the present invention provides the use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4 or an active derivative thereof.

Preferably the polypeptide is a CD4<sup>+</sup> T-cell stimulant.

According to a further aspect, there is provided a DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease, the construct comprising a sequence as shown in SEQIDNO1, or an active derivative

thereof.

In a still further aspect the invention provides a composition for use as a vaccine against neisserial disease, the composition comprising two peptides with the amino acid sequences as shown in SEQIDNO1 and SEQIDNO2, and SEQIDNO3 and SEQIDNO4 or active derivatives thereof.

In a further aspect of the present invention there is provided a nucleotide sequence comprising a base sequence as shown in SEQIDNO1, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2, or an active derivative thereof.

In a still further aspect of the present invention there is provided a nucleotide sequence comprising a base sequence as shown in SEQIDNO3, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4, or an active derivative thereof.

The invention also provides a vaccine against neisserial disease, the vaccine comprising polypeptide with some or all of the amino acid sequence as shown in SEQIDNO2, or an active derivative thereof.

The invention provides a further vaccine against neisserial disease, the vaccine comprising polypeptide with some or all of the amino acid sequence as shown in SEQIDNO4, or an active derivative thereof.

According to a further aspect of the present invention there is provided a method of treatment of neisserial disease, the method comprising inducing T-cell proliferation with polypeptide comprising one or both of the or some of the amino acid sequences shown in SEQIDNO2 and SEQIDNO4, or active derivative(s) thereof.

09743674-01001

The invention also provides a purified and isolated DNA composition comprising the sequence of SEQIDNO1 or SEQIDNO3, or an active derivative thereof.

Embodiments of the invention will now be described by way of example only and with reference to the accompanying drawings and sequences, in which:-

Fig. 1 is a graph illustrating the proliferation responses of peripheral blood mononuclear cells (PBMCs) of three patients and a healthy donor to meningococcal proteins.

Fig. 2 is a graph illustrating the proliferation indices of a T-cell line with fraction (SI-V) of meningococcal proteins separated by SDS PAGE.

Fig. 3 is a graph illustrating the proliferation indices of a T-cell line to subfractions A, B, C and D of section SI in Fig. 2, and also the proliferation index of concanavalin A (Con A) and whole cell lysate of iron-depleted meningococci (SD-).

SEQIDNO1 shows the nucleotide base sequence and the corresponding amino acid sequence of a gene and a polypeptide (TspA) encoded thereby, according to one aspect of the present invention;

SEQIDNO2 shows the polypeptide sequence of SEQIDNO1;

SEQIDNO3 shows the nucleotide base sequence and the corresponding amino acid sequence of a gene and a polypeptide (TspB) encoded thereby, according to another aspect of the present invention; and

SEQIDNO4 shows the polypeptide sequence of SEQIDNO3.

In order to identify meningococcal CD4<sup>+</sup> T-cell-stimulating peptides we adopted a number of different programmes all of which involve screening meningococcal peptide antigens, using meningococcal-specific CD4<sup>+</sup> T-cell lines and clones. These lines and clones have been generated over the past five years

or so, from the peripheral blood of normal donors and patients recovering from invasive meningococcal disease. *In-vitro* studies have been carried out with primed human T-cells obtained from naturally infected patients, with fresh peripheral blood samples obtained from patients at different stages of illness, namely the acute stage (on admission), early convalescence (seven days after admission), late convalescence (six weeks after discharge) and after full recovery (3 months and twelve months after discharge). T-cell lines and clones, specific to meningococcal proteins have been generated from the peripheral blood of patients recovering from meningococcal disease and healthy donors. The healthy donors were identified among twenty five volunteers by testing their peripheral blood mononuclear cells (PBMC) proliferation in response to meningococcal proteins.

#### Lymphocyte proliferation assays:

Briefly, PBMCs were isolated from heparinised blood samples by centrifugation over Histopaque (Sigma). The PBMCs were washed and cultured in 96-well tissue culture plates at  $2 \times 10^5$  cells/well in RPMI medium containing 10% human AB serum (RPMI-AB). Meningococcal proteins (from strain SD, B:15:P1,16) were prepared by growing the organism under iron restriction, to induce the expression of iron-regulated proteins which are also expressed *in vivo* [Ala'Aldeen, 1994]. The meningococcal proteins (SD-), antigens from *Candida albicans* (a recall antigen) or phytohaemagglutinin (PHA, positive control) were added to quadruplicate wells. RPMI-AB alone (with no antigen) was added to quadruplicate wells to serve as the background. After five days all cultures were pulsed with  $1\mu\text{Ci}$  of tritiated thymidine and incorporation of thymidine was determined after another eighteen hours. A positive response was defined as a PBMC proliferation index of at least 2 (see Fig. 1).

Continuous T-cell lines were established by culturing PBMCs with the meningococcal proteins and Interleukin 2 (IL-2) for five days, and activated T-cell blasts were stimulated to proliferate by a further nine days culture with IL-2 only. The lines were then maintained by weekly stimulation with proteins in

the presence of feeder cells and IL-2. Autologous Epstein-Barr virus transformed B-lymphocytes (EBVB) were used as antigen-presenting feeder cells following irradiation (6000R).

T-cell clones are defined here as the population of cells which originate from a single T-cell. Single T-cell receptors (TCRs) can engage with an extraordinary small number of peptide-HLA complexes (<10/cell) [Valitute, 1995], therefore T-cell clones will provide a highly sensitive system by which it will be possible to detect the presence of peptide antigens within mixtures of proteins. T-cell lines, specific to meningococcal antigens, were seeded at 0.3 cell/well in 96-well tissue culture plates in the presence of irradiated (non-proliferating) autologous EBVB feeder cells, plus low doses of IL-2 [Sinigaglia, 1991]. Cell growth was detected microscopically after one-two weeks and growing cells expanded further by stimulation with meningococcal proteins. All T-cell lines and clones were assessed for the phenotype (and ascertained to be CD4<sup>+</sup> T-cells), using flow cytometry and CD4, CD8 and  $\alpha/\beta$ - and  $\gamma/\delta$ - TCR-specific monoclonal antibodies. Their specificity to meningococcal proteins was tested by measurement of tritiated thymidine incorporation in response to stimulation with meningococcal proteins compared to irrelevant antigens e.g. tetanus toxoid. Large numbers of T-cell lines, oligoclones and clones from patients and normal donors have been identified and stored in liquid nitrogen until further use.

#### **T-cell responses to fractionated meningococcal proteins**

Meningococcal proteins were fractionated according to their molecular weights by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Two methods were used to prepare the separated proteins for addition to the T-cell cultures:

- a) Fractionated proteins were transferred onto nitrocellulose membranes which were transversely divided into five equal sections labelled SI-V, containing proteins of approximate molecular weight range >130 kDa, 70-130 kDa, 50-70 kDa, 34-50 kDa and <34 kDa, respectively. Membranes were then

solubilised with dimethyl sulphoxide and tested for their ability to stimulate T-cells using the established meningococcal specific T-cell lines. Using one of the cell lines, section SI (which contained proteins >130 kDa) caused greater T-cell proliferation than any of the other sections (Fig. 2). T-cell lines fed with either EBV-B-cells or fresh autologous PBMCs consistently gave similar results.

b) In the second method, SDS-gels containing the fractionated proteins were cut into transverse sections corresponding to the five fractions obtained by the nitrocellulose membrane method. The proteins were then directly eluted from the gel sections and purified by precipitation with organic solvents. This enabled measurement of the protein concentrations in each fraction and confirmation that differences in protein concentration were not responsible for the differences observed in Figure 2. Equivalent concentrations of purified proteins were used in lymphocyte proliferation assays. The results were consistent with those of the nitrocellulose membrane blot method (not shown).

Section SI consists of more than 12 proteins as seen on silver stained gels, ranging from 130-599 kDa (not shown). Therefore, it was subdivided into four fractions, FIA-D, and their proteins were eluted from gels as described above. The eluted proteins were tested for their ability to stimulate T-cell proliferation. As shown in Figure 3, using T-cell line of a patient, fractions FIC and D induced extremely high T-cell proliferation indices ( $\leq 30$ ), higher than fractions FIA and FIB, the whole of SI or the total SD-protein preparation. Another T-cell line showed the highest T-cell stimulation indices with fraction FIB and FIC, followed by FID, possibly reflecting the HLA specific response.

FIC was chosen for further characterisation and silver staining of SDS-gels showed that it contains four distinct protein bands (not shown). Rabbit polyclonal antibodies were raised to eluted FIC proteins and used to screen an already established genomic expression ( $\lambda$  Zap II) library. Several reactive meningococcal polypeptides and their respective DNA fragments were isolated. Two of the most promising ones (TspA and TspB) were further studied. The DNA fragments were sequenced and with help from the Sanger-released

genomic sequences which were produced by the *Neisseria Meningitidis* Sequencing Group at the Sanger Centre and can be obtained from <ftp://ftp.sanger.ac.uk/pub/AAREADME.release-policy.txt>, the genes encoding these two proteins were then constructed (see SEQIDNO1-4) and cloned into high expression vectors.

TspA, the abbreviation for T-cell stimulating protein A identified and characterised as part of the present invention has a genetic sequence substantially as shown in SEQIDNO1 and a corresponding polypeptide sequence as shown in SEQIDNO2.

TspA can be used to create a vaccine against pathogenic *neisseria*, and in particular *Neisseria meningitidis*, as well as *Neisseria gonorrhoea*. Determination of the sequence enables the generation of antibodies using general polyclonal and/or monoclonal techniques.

Similarly with TspB (T-cell stimulating protein B), vaccine or a component for a combination vaccine are created using polyclonal and/or monoclonal techniques.

It is envisaged that an effective vaccine will be a combination vaccine comprising a plurality of different antigens including TspA and TspB.

The exact sequences can vary among different isolates of meningococci due to the nature of the organism and its ability to mutate any gene any time. This is a universal problem inherent with any gene of these *Neisseria* organisms. Equivalent genes with homologous sequences exist in *Neisseria gonorrhoea*, as detected on the recently released gonococcal genomic sequence data obtained on the Internet from Oklahoma University, U.S.A.

Western blot experiments on TspA and TspB, using human convalescent sera, confirmed that both proteins are expressed in-vivo and stimulate B-cells following natural infection. The cloned proteins also induced strong CD4<sup>+</sup> T-

cell stimulatory effect in our T-cell proliferation assays. These suggested very clearly that they are promising vaccine candidates, and vaccines comprising one or both of these either together or with other proteins are therefore provided as part of this invention.

Finally, fractions FIB and FID, and Section SII and SV which produced net-positive T-cell stimulatory effects may consists of many T-cell stimulatory antigens (Fig. 1 and 3).

### Detection of T-cell antigens by phage-expression cloning

The present invention also provides a robust screening system for the identification of CD4<sup>+</sup> T-cell stimulating recombinant proteins, using an expression cloning protocol, which involves screening genomic meningococcal expression libraries.

#### 1. $\lambda$ ZapII Expression Library

This method had been successfully applied in other organisms to identify helper T-cell epitopes [Sanderson, 1995; Mougneau, 1995]. Briefly, we used an existing  $\lambda$ ZapII phage library expressing genomic DNA extracted from strain SD N. *meningitidis* [Palmer, 1993 #214]. The library contains  $2 \times 10^7$  recombinants with an average size of insert of 2.3 kb (range up to 10 kb). A representative pool of recombinant pBluescript SKII plasmid were excised (*in vivo*) from the phage library and transformed into *E. coli* strain XL1-Blue, using ExAssist helper phage (Stratgene) as described previously [Ala'Aldeen, 1996; Palmer, 1993].

Transformed *E. coli* with the pBluescript plasmid carrying meningococcal genes were diluted in selective culture media (containing ampicillin) and put in 96-well microtitre plates at 20-30 transformants/wells. The plates were incubated overnight at 37°C with shaking and replicate cultures were made by splitting the overnight cultures, and the original master plates stored at 4°C.



The splits were grown in epindorfs for 2-3 hours in fresh medium to  $OD_{600}=0.3$ , then incubated for an additional 2h with 1mM isopropyl-b-D-thio-galactoside (IPTG) to induce meningococcal protein expression. Bacteria were heat-killed, sonicated and added to the antigen presenting cells, and tested for their ability to stimulate individual T-cell lines and clones. Negative controls were sonicates of the same *E. coli* strain transformed with pBluescript SKII with no meningococcal DNA insert. Strong T-cell stimulating wells were identified and their corresponding reference wells diluted and subcultured. Up to 100 single colonies (representing single organisms with single plasmids) were isolated and re-screened for T-cell stimulation. Only potent T-cell stimulants were saved and further pursued. This aspect of the present invention proved highly rewarding, and so far two, previously unknown, potent T-cell stimulating meningococcal polypeptides have been identified and further characterised.

## 2. T-cell antigen detection using phage display libraries (PDL)

Displaying foreign peptides on the surface of bacteriophages is a relatively new but well-established technology. This is different from the normal phage libraries which carry the cloned genes and express and release the proteins inside a host bacterium and not on their own outer coat. In phage display libraries, displayed peptides are encoded as DNA inserts in the structural gene for one of the viral coat proteins and will then appear on the surface of the phage capsid. There are several phage display systems available, each with specific advantages. For example, some are filamentous and others are lytic, some are used as random display libraries (non-specific) which may be used to detect mimotopes, and others are more specific genomic libraries. It is important to note that most phage display libraries have been probed with antibodies in search of specific peptides. A highly novel approach comprising a further aspect of the present invention was developed involving the use of T-cell lines/clones to screen two different meningococcal genomic PDLs to identify good T-cell stimulating peptides.

### a) T7Select1 and T7Select415 PDL

One of the novel lytic bacteriophages is Novagen's T7Select Phage Display System which is easy to use and has the capacity to display peptides up to 1200 amino acids, equivalent to 3.6 kb, with protein molecular weight over 100kDa. Such high molecular weight proteins are usually expressed at low copy numbers by T7Select1. Phage T7Select415, however, is capable of displaying up to 415 copies of a peptide up to 50 amino acids in size. Phage assembly occurs in the *E. coli* cytoplasm and mature phages are released by cell lysis. The latter process occurs within a few hours of infection, which makes the system very rapid. To create a genomic display library, meningococcal DNA will be fragmented to appropriate sizes and cloned and packaged into both T7Select1 and T7Select415 vectors as described in the Novagen's T7Select System manual [Novagen, 1996]. This dual approach allows for the screening for both large and small polypeptides.

A representative population of these PDLs expressing meningococcal proteins are diluted and distributed as oligoclones into 96-well microtitre plates. To each well, appropriate *E. coli* host strains (BL21 for T7Select415 and BLT5403 for T7Select1) will be added to amplify the diluted phage population in these wells. The plates will be split into identical duplicates, one of which will be stored as the reference, and the other heat-killed and tested for the ability to stimulate the T-cell lines/clones as described above for the  $\lambda$ ZAPII library.

b)  $\lambda$ pRH825 random meningococcal epitope display library

Another method according to the present invention involves the use of proteins and small peptides on a modified lambda capsid protein D. This protein, which is of 11 kDa with 405 copies expressed as trimers on the phage head [Sternberg, 1995; Mikawa, 1996], is capable of an efficient display of foreign peptides that are fused to its amino- or carboxy-termini [Mikawa, 1996]. This system was successfully used to display a Hepatitis C genomic cDNA library [Alter, 1995] and, more recently, to generate a randomly amplified genomic PDL of known organisms [Lambert, 1993; Kwong-Kowk, 1996; Tomei,

1993]. This involves generating randomly amplified DNA fragments of a known DNA template, using short (random) oligonucleotide primers in polymerase chain reaction (PCR). We have recently constructed a meningococcal genomic lambda phage display library by cloning randomly amplified PCR products into  $\lambda$ prH825 vector, using two random primers, each tagged at 5' end to *Spe*I or *Not*I restriction sites to facilitate insertion into the predigested vector. Packaging amplified and digested DNA fragments into lambda phage was performed using a lambda packaging kit (Pharmacia Biotech) and plated by infection of the *E. coli* strain BB-4. This yielded  $5 \times 10^7$  plaques, of which a sample of 100 pfu were randomly chosen, and their DNA inserts sequenced. Sequence alignment of the obtained sequence data with those available for *N. Meningitidis* (Sanger, Wellcome) and/or *N. Gonorrhoea*, confirmed that all the chosen plaques contained DNA fragments of meningococcal origin. The fragment sizes ranged from 100-200 bp, representing deduced peptides of up to 60 amino acids long. This PDL was prepared and established in IRBM for use in the identification of CD4<sup>+</sup> T-cell stimulating recombinant peptides, using the same cloning technique described for the  $\lambda$ ZapII phage system.

Several selection criteria have been adopted to focus the search for relevant, potent and promiscuous T-cell epitopes.

Initially, only candidate peptides, which are likely to contain multiple T-cell epitopes that are immunogenic for CD4<sup>+</sup> Th-cells (not CD8<sup>+</sup> T-cells) and presented on MHC class II (HLA-DR, DQ or DP in humans) were studied. Only T-helper (Th) antigens, that bind to a number of widely ranging HLA-types, were selected. It will be determined whether each patient's CD4<sup>+</sup> Th-response to a candidate meningococcal peptide is due to an established memory Th population (CD45RO<sup>+</sup>) or to activation of naive T-cells (CD45RA<sup>+</sup>). Peptide candidates which activate either the Th2 subset of CD4<sup>+</sup> T-cell or the Th1 subset are selected. The therapeutic efficacy of both Th1 and Th2-inducing candidate peptides will be evaluated. T-cell clones specific for candidate antigens will be amplified and used to identify the individual T-cell epitopes.

In order to identify and then characterise core epitopes of each candidate peptide, progressively smaller fragments of the DNA will be cloned, expressed and further examined for T-cell stimulation. To define epitopes more accurately, short overlapping peptides representing the defined T-cell stimulating subunits are synthesised and re-examined. Then N- and C-terminal truncated analogs of the most immunogenic peptide fragment are synthesised and tested likewise. Finally, alanine scanning mutational analysis will be employed to identify critical amino acid positions responsible for both TCR contact and HLA-class II contact. Here, a series of peptide analogs of the core epitope identified after N- and C-terminal truncation are synthesised, each with a single alanine substituted at successive amino acid positions, and effects on T-cell immunogenicity and on HLA-binding are assessed [Nelson, 1996]. The isotype of class II HLA molecule restriction specificity will be identified for each T-cell clone by antibody blocking experiments.

As a part of the characterisation of the identified proteins, the diversity of these proteins among various strains of meningococci is studied. A large collection of clinical isolates of meningococci have been prepared, the proteins of these strains when purified (from the gels or clones), and tested for T-cell stimulatory capacity and characterised in a way similar to that used for strain SD will provide further vaccine candidates. Proteins that are expressed in all or more of these stains will be focused on.

#### Identification of HLA restriction

To determine whether different HLA class II molecules present different parts of individual proteins, one of two methods are used. The protein sub-fragments and their overlapping peptides described above will be tested for their capacity to stimulate T-cell clones generated from different individuals (volunteers or patients). Alternatively, lymphocyte donors will be HLA typed, and the association of responsiveness to particular proteins (or epitopes) and certain alleles of HLA-DR, -DQ or -DP determined.

A central aim is to identify T-cell immunogens of *N. meningitidis* which will stimulate T-cell help for the production of protective anti-meningococcal antibodies. Having identified dominant T-cell antigens amongst the proteins, their ability to stimulate T-cell help for antibody production is investigated *in vivo* in animals and in an *in vitro* immunisation system which has been established and optimised in our laboratories [Davenport, 1992]. Protein fragments or peptides that stimulate T-cells from individuals covering a range of HLA types are studied for the presence of B-cell epitopes. If the protein contains B-cell epitopes then antibodies from individuals naturally immune to meningococcal disease should recognise these proteins in immunoblots or ELISA. If no B-cell epitopes are recognised then the identified T-cell epitopes will be conjugated to previously characterised B-cell immunogens such as the meningococcal capsular polysaccharides, the class (1, 2/3) proteins, the transferrin binding proteins ... etc.

Whilst endeavouring in the foregoing specification to draw attention to the features of the invention believed to be of particular importance it should be understood that the Applicant claims protection in respect of any patentable feature hereinbefore referred to and/or shown in the drawings whether or not particular emphasis has been placed thereon.

ARTICLE 34

CLAIMS

1. A method of generating T-cell lines and clones specific to neisserial proteins, the method comprising isolating peripheral blood mononuclear cells (PBMCs) from the peripheral blood of normal donors and patients recovering from neisserial disease, culturing the PBMCs with neisserial proteins with or without a proliferation stimulant for a prescribed period, stimulating proliferation of T-cell lines and clones which are specific to neisserial proteins, and maintaining same by regular stimulation.

2. A method as claimed in claim 1, characterised in that the neisserial proteins are prepared from *Neisseria meningitidis* and/or *Neisseria gonorrhoea* grown under iron restrictions to induce the expression of iron-regulated proteins.

3. A method as claimed in any preceding claim, characterised in that the peripheral blood is obtained from naturally infected patients at different stages of illness.

4. A method as claimed in claim 3, characterised in that the stages include an acute stage (on admission), early convalescence (seven days after admission), late convalescence (six weeks after discharge) and after full recovery (3 months and twelve months after discharge).

5. A method as claimed in any preceding claim, characterised in that the peripheral blood is heparinised or treated with ESTA.

6. A method as claimed in any preceding claim, characterised in that the PBMCs are isolated from the blood by centrifugation.

7. A method as claimed in any preceding claim, characterised in that the PBMCs are initially cultured in medium containing human serum.

21-09-2000

GB 009902205

21

8. A method as claimed in any preceding claim, characterised in that the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period.

9. A method as claimed in claim 8, characterised in that the predetermined period is 3-10 days and may be 5 days.

10. A method as claimed in any of claims 8 or 9, characterised in that IL-2 stimulates the proliferation of the activated T-cell lines and clones.

11. A method as claimed in claim 10, characterised in that the T-cell lines and clones are maintained by weekly stimulation.

12. A method as claimed in claim 10 or claim 11, characterised in that the stimulation is provided by proteins in the presence of IL-2 and feeder cells.

13. A method as claimed in claim 12, characterised in that the feeder cells are antigen presenting feeder cells and may be autologous Epstein-Barr virus transformed B-lymphocytes (EBVB).

14. A method as claimed in any preceding claim, characterised in that the specificity of the T-cell lines and clones to neisserial proteins is tested prior to storing for example in liquid nitrogen.

15. A method as claimed in claim 14, characterised in that the specificity is tested by measurement of tritiated thymidine incorporation in response to stimulation with neisserial proteins compared to irrelevant antigens.

16. A method as claimed in claim 15, characterised in that an irrelevant antigen is tetanus toxoid.

17. A method as claimed in any preceding claim, characterised in that the phenotype of the T-cell lines and clones are also assessed using flow cytometry

and specific monoclonal antibodies.

18. A method as claimed in claim 17, characterised in that the antibodies are CD4<sup>+</sup>, CD8<sup>+</sup> and  $\alpha/\beta$ - and  $\gamma/\delta$ - T-cell receptor (TCR) specific monoclonal antibodies.

19. A method of detecting CD4<sup>+</sup> T-cell stimulating proteins, the method comprising fractionating neisserial proteins and testing the ability of said proteins to stimulate proliferation of Neisseria specific T-cell lines and clones generated according to the method as claimed in any of the preceding claims.

20. A method as claimed in claim 19, characterised in that the proteins are fractionated by SDS-PAGE.

21. A method as claimed in any of claims 19 or 20, characterised in that the fractions are tested for their ability to stimulate the individual T-cell lines and clones.

22. A method as claimed in claim 21, characterised in that fractions containing T-cell stimulants are further characterised by SDS-PAGE.

23. A method as claimed in any of claims 19 to 22, characterised in that polyclonal antibodies are raised to the T-cell stimulating fraction proteins.

24. A method as claimed in claim 23, characterised in that the antibodies are used to screen a genomic meningococcal and/or gonococcal expression library.

25. A method as claimed in claim 24, characterised in that the expression library is a  $\lambda$ ZapII library.

26. A method as claimed in claim 24 or claim 25, characterised in that isolated neisserial polypeptides which react with the antibodies and their respective DNA fragments are further characterised and sequenced.



27. A method of detecting CD4<sup>+</sup> T-cell stimulating recombinant proteins, the method comprising screening a genomic meningococcal or gonococcal expression library for recombinant proteins which stimulate T-cell lines and clones.

28. A method as claimed in claim 27, characterised in that the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method of any of claims 1 to 18.

9. A method as claimed in claim 27 or claim 28, characterised in that the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a strain of *Neisseria meningitidis* or a strain of *Neisseria gonorrhoea*.

10. A method as claimed in claim 29, characterised in that a representative pool of recombinant pBluescript SKII plasmid are excised from the phage library and transformed into *E.coli* strain XL1-Blue.

11. A method as claimed in claim 30, characterised in that the plasmids are excised into XL1-Blue using a helper phage.

32. A method as claimed in claim 30 or claim 31, characterised in that the transformed *E.coli* are cultured in a medium which may contain ampicillin.

33. A method as claimed in any of claims 27 to 32, characterised in that meningococcal or gonococcal protein expression is induced by isopropyl-b-D-thio-galactoside.

34. A method as claimed in any of claims 27 to 33, characterised in that the bacteria are heat-killed and sonicated before adding to antigen presenting cells.

35. A method as claimed in any of claims 27 to 34, characterised in that the expressed proteins are tested for their ability to stimulate the individual T-cell

lines and clones.

36. A method as claimed in any of claims 27 to 35, characterised in that CD4<sup>+</sup> T-cell stimulating bacterial cultures are identified and subcultured.

37. A method as claimed in claim 36, characterised in that the subcultures are preferably rescreened for T-cell stimulation.

38. A method as claimed in claim 36 or claim 37, characterised in that the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and are further characterised.

39. A method as claimed in any of claims 27 or 28, characterised in that the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a meningococcal or gonococcal genomic lambda phage display library.

40. A method of detecting CD4<sup>+</sup> T-cell stimulating peptides, the method comprising screening meningococcal or gonococcal genomic phage display libraries (PDLs) to identify peptides which stimulate T-cell lines and clones.

41. A method as claimed in claim 40, characterised in that the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method as claimed in any of claims 1 to 18.

42. A method as claimed in any of claims 39 to 41, characterised in that the genomic phage display library (PDL) is generated by fragmenting bacterial DNA, cloning and packaging into bacteriophage vectors.

43. A method as claimed in claim 42, characterised in that two vectors are used.

44. A method as claimed in claim 43, characterised in that the first vector

21-09-2000

GB 009902205

25

displays peptides up to 1200 amino acids which are expressed at low copy numbers.

45. A method as claimed in claim 43 or claim 44, characterised in that the second vector preferably displays up to 415 copies of a peptide up to 50 amino acids in size.

46. A method as claimed in any of claims 40 to 45, characterised in that the PDLs are amplified in respective *E.coli* hosts.

47. A method as claimed in any of claims 40 to 46, characterised in that the cells are heat killed before testing for the ability of the peptides to stimulate the T-cell lines and clones.

48. A method as claimed in any of claims 40 to 47, characterised in that CD4<sup>+</sup> T-cell stimulating PDL cultures are identified and subcultured.

49. A method as claimed in claim 48, characterised in that the subcultures are rescreened for T-cell stimulation.

50. A method as claimed in any of claims 40 to 49, characterised in that the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and are further characterised.

51. A method of detecting CD4<sup>+</sup> T-cell stimulating recombinant proteins, using a meningococcal or gonococcal genomic lambda phage display library in accordance with any of claims 27 to 39.

52. A method as claimed in claim 51, characterised in that the meningococcal or gonococcal genomic lambda phage display library is constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same into a pre-digested vector, and plating by infecting *E.coli*.

21-09-2000

GB 009902205

26

53. A method as claimed in claim 52, characterised in that the vector is a lambda phage.

54. A method as claimed in claim 53, characterised in that the vector is  $\lambda$ PRH825 vector.

55. A method as claimed in claim 53 or 54, characterised in that the amplified and digested DNA fragments are packaged into the lambda phage using a lambda phage packaging kit.

56. A method as claimed in any of claims 52 to 55, characterised in that the restriction sites are *SpeI* or *NotI*.

57. A method as claimed in any of claims 51 to 56, characterised in that the DNA inserts in the plaques formed are sequenced, thereby confirming that the plaques contain DNA fragments of meningococcal or gonococcal origin.

58. Use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2 or an active derivative thereof.

59. A polypeptide as claimed in claim 58, characterised in that the polypeptide is a CD4<sup>+</sup> T-cell stimulant.

60. A DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease the construct comprising a sequence as shown in SEQIDNO3 or an active derivative thereof.

61. Use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4 or an active derivative thereof.

62. A polypeptide as claimed in claim 61, characterised in that the

polypeptide is a CD4<sup>+</sup> T-cell stimulant.

63. A DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease, the construct comprising a sequence as shown in SEQIDNO1, or an active derivative thereof.

64. A composition for use as a vaccine against neisserial disease, the composition comprising two peptides with the amino acid sequences as shown in SEQIDNO1 and SEQIDNO2, and SEQIDNO3 and SEQIDNO4 or active derivatives thereof.

65. A nucleotide sequence comprising a base sequence as shown in SEQIDNO1, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2, or an active derivative thereof.

66. A nucleotide sequence comprising a base sequence as shown in SEQIDNO3, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4, or an active derivative thereof.

67. A vaccine against neisserial disease, the vaccine comprising polypeptide with the amino acid sequence as shown in SEQIDNO2 or an active derivative thereof.

68. A vaccine against neisserial disease, the vaccine comprising polypeptide with the amino acid sequence as shown in SEQIDNO4 or an active derivative thereof.

69. A method of treatment of neisserial disease, the method comprising inducing T-cell proliferation with polypeptide comprising one or both of the amino acid sequences shown in SEQIDNO2 and SEQIDNO4, or active derivative(s) thereof.

21-09-2000

GB 009902205

28

70. A purified and isolated DNA composite comprising the sequence shown in SEQIDNO1, or an active derivative thereof.

71. A purified and isolated DNA composition comprising the sequence shown in SEQIDNO3, or an active derivative thereof.

72. A methodology substantially as hereinbefore described with reference to the accompany drawings and sequences.

73. Use of a polypeptide substantially as hereinbefore described with reference to the accompany drawings and sequences.

74. A DNA construct substantially as hereinbefore described with reference to the accompany drawings and sequences.

75. A composition substantially as hereinbefore described with reference to the accompany drawings and sequences.




76. A nucleotide sequence substantially as hereinbefore described with reference to the accompany drawings and sequences.

77. A vaccine substantially as hereinbefore described with reference to the accompany drawings and sequences.

78. A method of treatment substantially as hereinbefore described with reference to the accompany drawings and sequences.

79. Any novel subject matter or combination including novel subject matter disclosed herein, whether or not within the scope of or relating to the same invention as any of the preceding claims.

1/1

**FIG. 1****FIG. 2****FIG. 3**

US

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY** (Continued Reference to PCT International Application)ATTORNEY'S DOCKET NUMBER  
15-846

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**SCREENING OF NEISSERIA VACCINE CANDIDATES AND VACCINES AGAINST PATHOGENIC NEISSERIA**

the specification of which (check only one item below):

☐ is attached hereto.☐ was filed as United States applicationSerial No. \_\_\_\_\_  
on \_\_\_\_\_  
and was amended  
on \_\_\_\_\_ (if applicable).☒ was filed as PCT international applicationNumber PCT/GB99/02205  
on 9 July 1999 (09.07.99)  
and was amended under PCT Article 19  
on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) or patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) or patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**

COUNTRY (if PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (Mm, Dddd, Yyyy)	PRIORITY CLAIMED UNDER 35 USC 119
PCT	PCT/GB99/02205	9 July 1999 (09.07.99)	10 July 1999 (10.07.99)
GREAT BRITAIN	9914902.4	10 July 1999 (10.07.99)	



S. JAN. 2001 12:58

SWINDELL AND PEARSON

NO. 379 P. 4/4

<b>Conditional Declaration for Patent Application and Power of Attorney (Continued)</b> (Subject to PCT International Application)			<b>ATTORNEY'S DOCKET NUMBER</b> 15-000	
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT International application(s) designating the United States of America that have been filed before and, insofar as the subject matter of such of the claims of this application is not disclosed in the above prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §120, I acknowledge the duty to disclose material information as defined in Title 35, Code of Federal Regulations, §1.56(d) which occurs between the filing date of the prior application(s) and the national or PCT International filing date of this application.</p>				
<b>FOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR PRIORITY UNDER 35 U.S.C. 120:</b>				
<b>U.S. APPLICATIONS</b>			<b>STATUS (Check One)</b>	
<b>U.S. APPLICATION NUMBER</b>	<b>U.S. FILING DATE</b>	<b>PATENTED</b>	<b>PENDING</b>	<b>ABANDONED</b>
<b>PCT APPLICATIONS DESIGNATING THE U.S.</b>				
<b>PCT APPLICATION NO.</b>	<b>PCT FILING DATE</b>	<b>U.S. SERIAL NUMBERS ASSIGNED (U.S. #)</b>		
PCT/GB99/02206	02.07.1999			
<p><b>VIEW OF ATTORNEY:</b> As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this invention and transmit all business in the Patent and Trademark Office connected therewith. (List name and registration number):          Fisher, Reg. No. 18,271; L.L. Holm, Reg. No. 19,671; J.C. Waterman, Reg. No. 20,130; L.J. Boney, Reg. No. 22,078;          Hlavka, Reg. No. 22,076; S.J. Schuka, Reg. No. 22,108; R.A. Sharpe, Reg. No. 24,722; G.L. Pindak, Reg. No. 27,587;          Seeborn, Reg. No. 24,439; R.J. Smith, Reg. No. 45,115 and William Johnson, Reg. No. 24,647.</p>				
<b>Correspondence to:</b> Richard A. Sharpe Wasm, Hoffmann, Fisher & Heinke Co. P.O. Box 99839 Cleveland, Ohio 44199-0839			<b>Direct Telephone Calls to:</b> (Area and telephone number) 216/241-6700	
<b>ILL. NAME INVENTOR</b>	<b>FAMILY NAME</b>	<b>FIRST GIVEN NAME</b>	<b>SECOND GIVEN NAME</b>	
	ALA ALDERN	Diwan		
<b>ADDRESS &amp; COUNTRY</b>	<b>CITY</b>	<b>STATE OR FOREIGN COUNTRY</b>	<b>COUNTRY OF CITIZENSHIP</b>	
	NOTTINGHAM (British)	United Kingdom GBX	Great Britain	
<b>TO OFFICE DESK</b>	<b>POST OFFICE ADDRESS</b>	<b>CITY</b>	<b>STATE &amp; ZIP CODE/COUNTRY</b>	
	12-Benington Drive	NOTTINGHAM	NG8 2TF	
<b>ILL. NAME INVENTOR</b>	<b>FAMILY NAME</b>	<b>FIRST GIVEN NAME</b>	<b>SECOND GIVEN NAME</b>	
	TODD	Jan		
<b>ADDRESS &amp; COUNTRY</b>	<b>CITY</b>	<b>STATE OR FOREIGN COUNTRY</b>	<b>COUNTRY OF CITIZENSHIP</b>	
	NOTTINGHAM (BRITISH)	United Kingdom GBX	Great Britain	
<b>OFFICE DESK</b>	<b>POST OFFICE ADDRESS</b>	<b>CITY</b>	<b>STATE &amp; ZIP CODE/COUNTRY</b>	
	28, HIGHFIELD RD.	KEYWORTH, NOTTINGHAM	NG12 5JE	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.</p>				
<b>SIGNATURE OF INVENTOR 101</b>		<b>SIGNATURE OF INVENTOR 202</b>		<b>SIGNATURE OF INVENTOR 303</b>
D. Aldern		J. Todd		
<b>DATE</b>		<b>DATE</b>		<b>DATE</b>
9/1/01		9/1/01		

(1) Information for SEQIDNO1:

(a) Sequence Characteristics:

- (i) Length : 2761 base pairs
- (ii) Type : Nucleic acid
- (iii) Strandedness : Double

(b) Molecule type : DNA (genomic)

(c) Original Source:

- (i) Organism : *Neisseria meningitidis*
- (ii) Strain : SD, serogroup B (B:15:Pl.16)

0943674-01001  
PCT/PTO 10 JAN 2001

## (2) Information for SEQIDNO2:

## (a) Sequence Characteristics:

- (i) Length : 880 amino acids
- (ii) Type : amino acid
- (iii) Topology : linear

## (b) Molecule type : protein

## (c) Original Source:

- (i) Organism : *Neisseria meningitidis*
- (ii) Strain : SD, serogroup B (B:15:Pl.16)

## (3) Information for SEQIDNO3:

- (a) Sequence Characteristics:
  - (i) Length : 1647 base pairs
  - (ii) Type : Nucleic acid
  - (iii) Strandedness : Double
- (b) Molecule type : DNA (genomic)
- (c) Original Source:
  - (i) Organism : *Neisseria meningitidis*
  - (ii) Strain : SD, serogroup B (B:15:Pl.16)

## (4) Information for SEQIDNO4:

## (a) Sequence Characteristics:

- (i) Length : 548 amino acids
- (ii) Type : amino acid
- (iii) Topology : linear

## (b) Molecule type : protein

## (c) Original Source:

- (i) Organism : *Neisseria meningitidis*
- (ii) Strain : SD, serogroup B (B:15:Pl.16)

## SEQUENCE LISTING

<110> The University of Nottingham

<120> Screening of Neisserial Vaccine Candidates and Vaccines  
against Pathogenic Neisseria.

<130> NW/6943INT

<140> PCT/GB99/02205

<141> 1999-07-09

<150> 9814902.4

<151> 1998-07-10

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 2761

<212> DNA

<213> Neisseria meningitidis

<220>

<221> CDS

<222> (119)..(2761)

<400> 1

```

gattgatgca aatatgcaca gatgtttttg aaaaaagatg gagatatgtc ataatttgta 60
aaaacggcga atgattgcgc tttaaaaatgt ggcggcgggc ggtacattca catattaa 118
atg ccc gcc gcc cga ctg ccc cgc cga tgc ccg atg atg acg aaa ttt 166
Met Pro Ala Gly Arg Leu Pro Arg Arg Cys Pro Met Met Thr Lys Phe
      1              5              10              15
aca gac tgt acg cgg tca aac cgt att cag ccg cca acc cac agg gga 214
Thr Asp Cys Thr Arg Ser Asn Arg Ile Gln Pro Pro Thr His Arg Gly
      20              25              30
tac atc ttg aaa aac aac aga caa atc aaa ctg att gcc gcc tcc gtc 262
Tyr Ile Leu Lys Asn Asn Arg Gln Ile Lys Leu Ile Ala Ala Ser Val
      35              40              45
gca gtt gcc gca tcc ttt cag gca cat gct gga ctg ggc gga ctg aat 310
Ala Val Ala Ala Ser Phe Gln Ala His Ala Gly Leu Gly Gly Leu Asn
      50              55              60

```

atc cag tcc aac ctt gac gaa ccc ttt tcc ggc agc att acc gta acc 358  
 Ile Gln Ser Asn Leu Asp Glu Pro Phe Ser Gly Ser Ile Thr Val Thr  
 65 70 75 80

ggc gaa gaa gcc aaa gcc ctg cta ggc ggc ggc agc gtt acc gtt tcc 406  
 Gly Glu Glu Ala Lys Ala Leu Leu Gly Gly Gly Ser Val Thr Val Ser  
 85 90 95

gaa aaa ggc ctg acc gcc aaa gtc cac aag ttg ggc gac aaa gcc gtc 454  
 Glu Lys Gly Leu Thr Ala Lys Val His Lys Leu Gly Asp Lys Ala Val  
 100 105 110

att gcc gtt tct tcc gaa cag gca gtc cgc gat ccc gtc ctg gta ttc 502  
 Ile Ala Val Ser Ser Glu Gln Ala Val Arg Asp Pro Val Leu Val Phe  
 115 120 125

cgc atc ggc gca ggc gca cag gta cgc gaa tac acc gcc atc ctc gat 550  
 Arg Ile Gly Ala Gly Ala Gln Val Arg Glu Tyr Thr Ala Ile Leu Asp  
 130 135 140

cct gtc ggc tac tcc ccc aaa acc aaa tct gca ctt tca gac ggc aag 598  
 Pro Val Gly Tyr Ser Pro Lys Thr Lys Ser Ala Leu Ser Asp Gly Lys  
 145 150 155 160

aca cac cgc aaa acc gct ccg aca gca gag tcc caa gaa aat caa aac 646  
 Thr His Arg Lys Thr Ala Pro Thr Ala Glu Ser Gln Glu Asn Gln Asn  
 165 170 175

gcc aaa gcc ctc cgc aaa acc gat aaa aaa gac agc gcg aac gca gcc 694  
 Ala Lys Ala Leu Arg Lys Thr Asp Lys Lys Asp Ser Ala Asn Ala Ala  
 180 185 190

gtc aaa ccg gcg tac aac gcc aaa acc cat acc gtc cgc aaa gcc gaa 742  
 Val Lys Pro Ala Tyr Asn Gly Lys Thr His Thr Val Arg Lys Gly Glu  
 195 200 205

acg gtc aaa cag att gcc gcc gcc atc cgc ccg aaa cac ctg acg ctc 790  
 Thr Val Lys Gln Ile Ala Ala Ala Ile Arg Pro Lys His Leu Thr Leu  
 210 215 220

gaa cag gtt gcc gat gcg ctg ctg aag gca aac cca aat gtt tcc gca 838  
 Glu Gln Val Ala Asp Ala Leu Leu Lys Ala Asn Pro Asn Val Ser Ala  
 225 230 235 240

cac ggc aga ctg cgt gcg ggc agc gtc ctt cac att ccg aat ctg aac 886  
 His Gly Arg Leu Arg Ala Gly Ser Val Leu His Ile Pro Asn Leu Asn  
 245 250 255

agg atc aaa gcg gaa caa ccc aaa ccg caa acg gcg aaa ccc aaa gcc 934  
 Arg Ile Lys Ala Glu Gln Pro Lys Pro Gln Thr Ala Lys Pro Lys Ala  
 260 265 270

gaa acc gca tcc atg ccg tcc gaa ccg tcc aaa cag gca acg gta gag 962  
 Glu Thr Ala Ser Met Pro Ser Glu Pro Ser Lys Gln Ala Thr Val Glu  
 275 280 285

aaa ccg gtt gaa aaa cct gaa gca aaa gtt gcc gcg ccc gaa gca aaa 1030  
 Lys Pro Val Glu Lys Pro Glu Ala Lys Val Ala Ala Pro Glu Ala Lys  
 290 295 300

gcg gaa aaa ccg gcc gtt cga ccc gaa cct gta ccc gct gca aat act 1078  
 Ala Glu Lys Pro Ala Val Arg Pro Glu Pro Val Pro Ala Ala Asn Thr  
 305 310 315 320

gcc gca tcc gaa acc gct gcc gaa tcc gcc ccc caa gaa gcc gcc gct 1126  
 Ala Ala Ser Glu Thr Ala Ala Glu Ser Ala Pro Gln Glu Ala Ala Ala  
 325 330 335

tct gcc atc gac acg ccg acc gac gaa acc ggt aac gcc gtt tcc gaa 1174  
 Ser Ala Ile Asp Thr Pro Thr Asp Glu Thr Gly Asn Ala Val Ser Glu  
 340 345 350

cct gtc gaa cag gtt tct gcc gaa gaa gaa acc gaa agc gga ctg ttc 1222  
 Pro Val Glu Gln Val Ser Ala Glu Glu Glu Thr Glu Ser Gly Leu Phe  
 355 360 365

ggc ggt tcc tac acc ttg ctg ctt gcc ggc gga ggc gcg gca ttg atc 1270  
 Gly Gly Ser Tyr Thr Leu Leu Leu Ala Gly Gly Gly Ala Ala Leu Ile  
 370 375 380

gcc ctg ctg ctg ctt ttg cgc ctt gcc caa tcc aaa cgc gcg cgc cgt 1318  
 Ala Leu Leu Leu Leu Leu Arg Leu Ala Gln Ser Lys Arg Ala Arg Arg  
 385 390 395 400

acc gaa gaa tcc gtc cct gag gaa gag cct gac ctt gac gac gcg gca 1366  
 Thr Glu Glu Ser Val Pro Glu Glu Glu Pro Asp Leu Asp Asp Ala Ala  
 405 410 415

gac gac ggc ata gaa atc acc ttt gcc gaa gtc gaa act ccg gca acg 1414  
 Asp Asp Gly Ile Glu Ile Thr Phe Ala Glu Val Glu Thr Pro Ala Thr  
 420 425 430

ccc gaa ccc gct ccg aaa aac gat gta aac gac aca ctt gcc tta gat 1462  
 Pro Glu Pro Ala Pro Lys Asn Asp Val Asn Asp Thr Leu Ala Leu Asp  
 435 440 445



ggg gaa tct gaa gaa gag ttg tgg gca aaa caa acg ttc gat gtc gaa 1510  
 Gly Glu Ser Glu Glu Glu Leu Ser Ala Lys Gln Thr Phe Asp Val Glu  
 450 455 460

acc gat acg cct tcc aac cgc atc gac ttg gat ttc gac agc ctg gca 1558  
 Thr Asp Thr Pro Ser Asn Arg Ile Asp Leu Asp Phe Asp Ser Leu Ala  
 465 470 475 480

gcc gcg caa aac ggc att tta tcc ggc gca ctt acg cag gat gaa gaa 1606  
 Ala Ala Gln Asn Gly Ile Leu Ser Gly Ala Leu Thr Gln Asp Glu Glu  
 485 490 495

acc caa aaa cgc gcg gat gcc gat tgg aac gcc atc gaa tcc aca gac 1654  
 Thr Gln Lys Arg Ala Asp Ala Asp Trp Asn Ala Ile Glu Ser Thr Asp  
 500 505 510

agc gtg tac gag ccc gag acc ttc aac ccg tac aac cct gtc gaa atc 1702  
 Ser Val Tyr Glu Pro Glu Thr Phe Asn Pro Tyr Asn Pro Val Glu Ile  
 515 520 525

gtc atc gac acg ccc gaa ccg gaa tct gtc gcc caa act gcc gaa aac 1750  
 Val Ile Asp Thr Pro Glu Pro Glu Ser Val Ala Gln Thr Ala Glu Asn  
 530 535 540

aaa ccg gaa acc gtc gat acc gat ttc tcc gac aac ctg ccc tca aac 1798  
 Lys Pro Glu Thr Val Asp Thr Asp Phe Ser Asp Asn Leu Pro Ser Asn  
 545 550 555 560

aac cat atc ggc aca gaa gaa aca ggt tcc gca aaa cct gcc tca ccc 1846  
 Asn His Ile Gly Thr Glu Glu Thr Ala Ser Ala Lys Pro Ala Ser Pro  
 565 570 575

tcc gga ctg gca ggc ttc ctg aag ggt tcc tgg ccc gaa acc atc ttg 1894  
 Ser Gly Leu Ala Gly Phe Leu Lys Ala Ser Ser Pro Glu Thr Ile Leu  
 580 585 590

gaa aaa aca gtt gcc gaa gtc caa aca ccg gaa gag ttg cac gat ttc 1942  
 Glu Lys Thr Val Ala Glu Val Gln Thr Pro Glu Glu Leu His Asp Phe  
 595 600 605

ctg aaa gtg tac gaa acc gat gcc gtc gcg gaa act gcg cct gaa acg 1990  
 Leu Lys Val Tyr Glu Thr Asp Ala Val Ala Glu Thr Ala Pro Glu Thr  
 610 615 620

ccc gat ttc aac gcc gcc gca gac gat ttg tcc gca ttg ctt caa cct 2038  
 Pro Asp Phe Asn Ala Ala Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro  
 625 630 635 640

gcc gaa gca ccg tcc gtt gag gaa aat ata acg gaa acc gtt gcc gaa Ala Glu Ala Pro Ser Val Glu Glu Asn Ile Thr Glu Thr Val Ala Glu 645 650 655	2086
aca ccc gac ttc aac gcc acc gca gac gat ttg tcc gca tta ctt caa Thr Pro Asp Phe Asn Ala Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln 660 665 670	2134
cct tct gaa gta cct gcc gtt gag gaa aat gca gcg gaa atc gtt gcc Pro Ser Glu Val Pro Ala Val Glu Glu Asn Ala Ala Glu Ile Val Ala 675 680 685	2182
gat gat ttg tcc gca ctg ttg caa cct gct gaa gca ccg gct gtt gag Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Ala Pro Ala Val Glu 690 695 700	2230
gaa aat gta acg gaa act gtt gcc gaa acg tcc gac ttc cac acc gcc Glu Asn Val Thr Glu Thr Val Ala Glu Thr Ser Asp Phe His Thr Ala 705 710 715 720	2278
gca gac gat ttg tcc gca ctg ttg caa cct gct gaa gta ccg gcc gtt Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Val Pro Ala Val 725 730 735	2326
gag gaa aat gta acg aaa acc gtt gcc gaa ata cct gat ttc aac gcc Glu Glu Asn Val Thr Lys Thr Val Ala Glu Ile Pro Asp Phe Asn Ala 740 745 750	2374
acc gca gac gat ttg tcc gca tta ctt caa cct tct gaa gta ccg gcc Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ser Glu Val Pro Ala 755 760 765	2422
gtt gag gaa aat gca gcg gaa atc acc ttg gaa acg cct gat tcc aac Val Glu Glu Asn Ala Ala Glu Ile Thr Leu Glu Thr Pro Asp Ser Asn 770 775 780	2470
acc tct gag gca gac gct ttg ccc gac ttc ctg aaa gac ggc gag gag Thr Ser Glu Ala Asp Ala Leu Pro Asp Phe Leu Lys Asp Gly Glu Glu 785 790 795 800	2518
gaa acg gta gat ttg agc atc tac ctc tcg gaa gaa aat atc cca aat Glu Thr Val Asp Trp Ser Ile Tyr Leu Ser Glu Glu Asn Ile Pro Asn 805 810 815	2566
aat gca gat acc agt ttc cct tcg gaa tct gta ggt tct gac gcg cct Asn Ala Asp Thr Ser Phe Pro Ser Glu Ser Val Gly Ser Asp Ala Pro 820 825 830	2614

tcc gaa gcg aaa tac gac ctt gcc gaa atg tat ctg gaa atc gcc gac 2662  
 Ser Glu Ala Lys Tyr Asp Leu Ala Glu Met Tyr Leu Glu Ile Gly Asp  
 835 840 845

cgc gat gcc gct gcc gag aca gtg cag aaa ttg ctg gaa gaa gcc gaa 2710  
 Arg Asp Ala Ala Ala Glu Thr Val Gln Lys Leu Leu Glu Glu Ala Glu  
 850 855 860

ggc gac gta ctg aaa cgt gcc caa gca ttg gcg cag gaa ttg ggt att 2758  
 Gly Asp Val Leu Lys Arg Ala Gln Ala Leu Ala Gln Glu Leu Gly Ile  
 865 870 875 880

tga 2761

&lt;210&gt; 2

&lt;211&gt; 880

&lt;212&gt; PRT

&lt;213&gt; Neisseria meningitidis

&lt;400&gt; 2

Met Pro Ala Gly Arg Leu Pro Arg Arg Cys Pro Met Met Thr Lys Phe  
 1 5 10 15

Thr Asp Cys Thr Arg Ser Asn Arg Ile Gln Pro Pro Thr His Arg Gly  
 20 25 30

Tyr Ile Leu Lys Asn Asn Arg Gln Ile Lys Leu Ile Ala Ala Ser Val  
 35 40 45

Ala Val Ala Ala Ser Phe Gln Ala His Ala Gly Leu Gly Gly Leu Asn  
 50 55 60

Ile Gln Ser Asn Leu Asp Glu Pro Phe Ser Gly Ser Ile Thr Val Thr  
 65 70 75 80

Gly Glu Glu Ala Lys Ala Leu Leu Gly Gly Gly Ser Val Thr Val Ser  
 85 90 95

Glu Lys Gly Leu Thr Ala Lys Val His Lys Leu Gly Asp Lys Ala Val  
 100 105 110

Ile Ala Val Ser Ser Glu Gln Ala Val Arg Asp Pro Val Leu Val Phe  
 115 120 125

Arg Ile Gly Ala Gly Ala Gln Val Arg Glu Tyr Thr Ala Ile Leu Asp

130 135 140  
 Pro Val Gly Tyr Ser Pro Lys Thr Lys Ser Ala Leu Ser Asp Gly Lys  
 145 150 155 160  
 Thr His Arg Lys Thr Ala Pro Thr Ala Glu Ser Gln Glu Asn Gln Asn  
 165 170 175  
 Ala Lys Ala Leu Arg Lys Thr Asp Lys Lys Asp Ser Ala Asn Ala Ala  
 180 185 190  
 Val Lys Pro Ala Tyr Asn Gly Lys Thr His Thr Val Arg Lys Gly Glu  
 195 200 205  
 Thr Val Lys Gln Ile Ala Ala Ala Ile Arg Pro Lys His Leu Thr Leu  
 210 215 220  
 Glu Gln Val Ala Asp Ala Leu Leu Lys Ala Asn Pro Asn Val Ser Ala  
 225 230 235 240  
 His Gly Arg Leu Arg Ala Gly Ser Val Leu His Ile Pro Asn Leu Asn  
 245 250 255  
 Arg Ile Lys Ala Glu Gln Pro Lys Pro Gln Thr Ala Lys Pro Lys Ala  
 260 265 270  
 Glu Thr Ala Ser Met Pro Ser Glu Pro Ser Lys Gln Ala Thr Val Glu  
 275 280 285  
 Lys Pro Val Glu Lys Pro Glu Ala Lys Val Ala Ala Pro Glu Ala Lys  
 290 295 300  
 Ala Glu Lys Pro Ala Val Arg Pro Glu Pro Val Pro Ala Ala Asn Thr  
 305 310 315 320  
 Ala Ala Ser Glu Thr Ala Ala Glu Ser Ala Pro Gln Glu Ala Ala Ala  
 325 330 335  
 Ser Ala Ile Asp Thr Pro Thr Asp Glu Thr Gly Asn Ala Val Ser Glu  
 340 345 350  
 Pro Val Glu Gln Val Ser Ala Glu Glu Glu Thr Glu Ser Gly Leu Phe  
 355 360 365  
 Gly Gly Ser Tyr Thr Leu Leu Leu Ala Gly Gly Gly Ala Ala Leu Ile  
 370 375 380  
 Ala Leu Leu Leu Leu Leu Arg Leu Ala Gln Ser Lys Arg Ala Arg Arg

385                      390                      395                      400  
 Thr Glu Glu Ser Val Pro Glu Glu Glu Pro Asp Leu Asp Asp Ala Ala  
                                  405                      410                      415  
 Asp Asp Gly Ile Glu Ile Thr Phe Ala Glu Val Glu Thr Pro Ala Thr  
                                  420                      425                      430  
 Pro Glu Pro Ala Pro Lys Asn Asp Val Asn Asp Thr Leu Ala Leu Asp  
                                  435                      440                      445  
 Gly Glu Ser Glu Glu Glu Leu Ser Ala Lys Gln Thr Phe Asp Val Glu  
                                  450                      455                      460  
 Thr Asp Thr Pro Ser Asn Arg Ile Asp Leu Asp Phe Asp Ser Leu Ala  
 465                                   470                      475                      480  
 Ala Ala Gln Asn Gly Ile Leu Ser Gly Ala Leu Thr Gln Asp Glu Glu  
                                  485                      490                      495  
 Thr Gln Lys Arg Ala Asp Ala Asp Trp Asn Ala Ile Glu Ser Thr Asp  
                                  500                      505                      510  
 Ser Val Tyr Glu Pro Glu Thr Phe Asn Pro Tyr Asn Pro Val Glu Ile  
                                  515                      520                      525  
 Val Ile Asp Thr Pro Glu Pro Glu Ser Val Ala Gln Thr Ala Glu Asn  
                                  530                      535                      540  
 Lys Pro Glu Thr Val Asp Thr Asp Phe Ser Asp Asn Leu Pro Ser Asn  
 545                                   550                      555                      560  
 Asn His Ile Gly Thr Glu Glu Thr Ala Ser Ala Lys Pro Ala Ser Pro  
                                  565                      570                      575  
 Ser Gly Leu Ala Gly Phe Leu Lys Ala Ser Ser Pro Glu Thr Ile Leu  
                                  580                      585                      590  
 Glu Lys Thr Val Ala Glu Val Gln Thr Pro Glu Glu Leu His Asp Phe  
                                  595                      600                      605  
 Leu Lys Val Tyr Glu Thr Asp Ala Val Ala Glu Thr Ala Pro Glu Thr  
                                  610                      615                      620  
 Pro Asp Phe Asn Ala Ala Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro  
 625                                   630                      635                      640  
 Ala Glu Ala Pro Ser Val Glu Glu Asn Ile Thr Glu Thr Val Ala Glu

	645		650		655
Thr Pro Asp Phe Asn Ala Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln	660		665		670
Pro Ser Glu Val Pro Ala Val Glu Glu Asn Ala Ala Glu Ile Val Ala	675		680		685
Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Ala Pro Ala Val Glu	690		695		700
Glu Asn Val Thr Glu Thr Val Ala Glu Thr Ser Asp Phe His Thr Ala	705		710		715
Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Val Pro Ala Val	725		730		735
Glu Glu Asn Val Thr Lys Thr Val Ala Glu Ile Pro Asp Phe Asn Ala	740		745		750
Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ser Glu Val Pro Ala	755		760		765
Val Glu Glu Asn Ala Ala Glu Ile Thr Leu Glu Thr Pro Asp Ser Asn	770		775		780
Thr Ser Glu Ala Asp Ala Leu Pro Asp Phe Leu Lys Asp Gly Glu Glu	785		790		795
Glu Thr Val Asp Trp Ser Ile Tyr Leu Ser Glu Glu Asn Ile Pro Asn	805		810		815
Asn Ala Asp Thr Ser Phe Pro Ser Glu Ser Val Gly Ser Asp Ala Pro	820		825		830
Ser Glu Ala Lys Tyr Asp Leu Ala Glu Met Tyr Leu Glu Ile Gly Asp	835		840		845
Arg Asp Ala Ala Ala Glu Thr Val Gln Lys Leu Leu Glu Glu Ala Glu	850		855		860
Gly Asp Val Leu Lys Arg Ala Gln Ala Leu Ala Gln Glu Leu Gly Ile	865		870		875
					880

&lt;210&gt; 3

&lt;211&gt; 1647

&lt;212&gt; DNA

&lt;213&gt; Neisseria meningitidis

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1647)

&lt;400&gt; 3

atg aag caa aat gtt atg ttt ctt atc cta ggg cga aat ttt tta aag	48
Met Lys Gln Asn Val Met Phe Leu Ile Leu Gly Arg Asn Phe Leu Lys	
1 5 10 15	
att atc cta tgc ttt agt ttt ttt gta cct aaa ttt gca ttg gca tca	96
Ile Ile Leu Cys Phe Ser Phe Phe Val Pro Lys Phe Ala Leu Ala Ser	
20 25 30	
gta aat gtt ccg ggt aaa ttt gat agg gtt gaa gtt tat gat gat ggc	144
Val Asn Val Pro Gly Lys Phe Asp Arg Val Glu Val Tyr Asp Asp Gly	
35 40 45	
aga tat tta ggt att cga ggt tca gat gac aaa aga aga aga att tgg	192
Arg Tyr Leu Gly Ile Arg Gly Ser Asp Asp Lys Arg Arg Arg Ile Trp	
50 55 60	
aaa ggt gta ttt gat aga gaa tcg gga aga tat tta act tca gaa gct	240
Lys Gly Val Phe Asp Arg Glu Ser Gly Arg Tyr Leu Thr Ser Glu Ala	
65 70 75 80	
caa gat tta aaa gtt agg cat gta tct act gga gca tca agt acg ggt	288
Gln Asp Leu Lys Val Arg His Val Ser Thr Gly Ala Ser Ser Thr Gly	
85 90 95	
aaa gtt agt tcg gtt gta tct tca tca gtt tcc cgc gcc gga gtc ttg	336
Lys Val Ser Ser Val Val Ser Ser Ser Val Ser Arg Ala Gly Val Leu	
100 105 110	
gca gga gtc ggc aaa ctt gcc cgc tta ggc gcg aaa tta agc aca agg	384
Ala Gly Val Gly Lys Leu Ala Arg Leu Gly Ala Lys Leu Ser Thr Arg	
115 120 125	
gca gtt cct tat gtc gga aca gcc ctt tta gcc cat gac gta tac gaa	432
Ala Val Pro Tyr Val Gly Thr Ala Leu Leu Ala His Asp Val Tyr Glu	
130 135 140	
act ttc aaa gaa gac ata cag gca caa ggc tac caa tac gac ccc gaa	480
Thr Phe Lys Glu Asp Ile Gln Ala Gln Gly Tyr Gln Tyr Asp Pro Glu	
145 150 155 160	

acc gac aaa ttt gta aaa ggc tac gaa tat agt aat tgc ctt tgg tac 528  
 Thr Asp Lys Phe Val Lys Gly Tyr Glu Tyr Ser Asn Cys Leu Trp Tyr  
 165 170 175

gaa gac aaa aga cgt att aat aga acc tat ggc tgc tac ggc gtt gac 576  
 Glu Asp Lys Arg Arg Ile Asn Arg Thr Tyr Gly Cys Tyr Gly Val Asp  
 180 185 190

agt tcg att atg cgc ctt atg tcc gat gac agc aga ttc ccc gaa gtc 624  
 Ser Ser Ile Met Arg Leu Met Ser Asp Asp Ser Arg Phe Pro Glu Val  
 195 200 205

aaa gaa ttg atg gaa agc caa atg tat agg ctg gca cgt ccg ttt tgg 672  
 Lys Glu Leu Met Glu Ser Gln Met Tyr Arg Leu Ala Arg Pro Phe Trp  
 210 215 220

aat tgg cat aaa gaa gaa ctg aat aaa tta agt tct ttg gat tgg aat 720  
 Asn Trp His Lys Glu Glu Leu Asn Lys Leu Ser Ser Leu Asp Trp Asn  
 225 230 235 240

aat ttt gtt tta aat cgt tgc aca ttt aat tgg aat ggc gga gat tgt 768  
 Asn Phe Val Leu Asn Arg Cys Thr Phe Asn Trp Asn Gly Gly Asp Cys  
 245 250 255

ttg gtc aat aaa ggt gat gat ttc aga aat ggg gct gat ttt tcc ctt 816  
 Leu Val Asn Lys Gly Asp Asp Phe Arg Asn Gly Ala Asp Phe Ser Leu  
 260 265 270

att cgc aat tca aaa tac aaa gaa gaa atg gat gcc aaa aag ctg gaa 864  
 Ile Arg Asn Ser Lys Tyr Lys Glu Glu Met Asp Ala Lys Lys Leu Glu  
 275 280 285

gag att tta tcg ttg aaa gtc gat gcc aat ccc gac aaa tac ata aag 912  
 Glu Ile Leu Ser Leu Lys Val Asp Ala Asn Pro Asp Lys Tyr Ile Lys  
 290 295 300

gaa acc ggt tat ccc ggt tat tcc gaa aaa gta gaa gtc gca ccc gga 960  
 Glu Thr Gly Tyr Pro Gly Tyr Ser Glu Lys Val Glu Val Ala Pro Gly  
 305 310 315 320

aca aaa gtg aat atg ggt ccc gtc acg gac agg aac ggg aat ccc gtt 1008  
 Thr Lys Val Asn Met Gly Pro Val Thr Asp Arg Asn Gly Asn Pro Val  
 325 330 335

cag gtt gtc gca aca ttc ggc agg gat tcg caa ggc aac acc acg gtg 1056  
 Gln Val Val Ala Thr Phe Gly Arg Asp Ser Gln Gly Asn Thr Thr Val  
 340 345 350



gat gtt caa gta atc ccg cgt ccc gac ttg acc ccc gga agc gcg gaa 1104  
 Asp Val Gln Val Ile Pro Arg Pro Asp Leu Thr Pro Gly Ser Ala Glu  
 355 360 365

gca ccg aac gca cag ccg ctg ccc gaa gta tgg ccc gcc gaa aac ccc 1152  
 Ala Pro Asn Ala Gln Pro Leu Pro Glu Val Ser Pro Ala Glu Asn Pro  
 370 375 380

gca aac aac ccg aac ccc aat gag aac ccc ggc acg agc ccc aat ccc 1200  
 Ala Asn Asn Pro Asn Pro Asn Glu Asn Pro Gly Thr Ser Pro Asn Pro  
 385 390 395 400

gaa ccc gac ccc gat ttg aat ccc gat gca aat ccc gat acg gac gga 1248  
 Glu Pro Asp Pro Asp Leu Asn Pro Asp Ala Asn Pro Asp Thr Asp Gly  
 405 410 415

cag ccc ggc aca aga ccc gat tcc ccc gcc gtt ccg gga cgc aca aac 1296  
 Gln Pro Gly Thr Arg Pro Asp Ser Pro Ala Val Pro Gly Arg Thr Asn  
 420 425 430

ggc agg gac ggc aaa gac gga aag gac ggc aaa gat ggc ggc ctt ttg 1344  
 Gly Arg Asp Gly Lys Asp Gly Lys Asp Gly Lys Asp Gly Gly Leu Leu  
 435 440 445

tgc aaa ttc ttc ccc gac att ctc gct tgc gac agg ctg ccc gag tcc 1392  
 Cys Lys Phe Phe Pro Asp Ile Leu Ala Cys Asp Arg Leu Pro Glu Ser  
 450 455 460

aat ccg gca gaa gat tta aat ctg ccg tct gaa acc gtc aat gta gag 1440  
 Asn Pro Ala Glu Asp Leu Asn Leu Pro Ser Glu Thr Val Asn Val Glu  
 465 470 475 480

ttt cag aaa tca gga atc ttt caa gat tcc gca cag tgt ccc gca cct 1488  
 Phe Gln Lys Ser Gly Ile Phe Gln Asp Ser Ala Gln Cys Pro Ala Pro  
 485 490 495

gtc act ttc aca gtg act gtg ctt gat tca agc agg cag ttc gcg ttc 1536  
 Val Thr Phe Thr Val Thr Val Leu Asp Ser Ser Arg Gln Phe Ala Phe  
 500 505 510

agc ttt gag aac gca tgt acc ata gcc gaa cgg cta agg tac atg ctt 1584  
 Ser Phe Glu Asn Ala Cys Thr Ile Ala Glu Arg Leu Arg Tyr Met Leu  
 515 520 525

ctc gcc ctt gct tgg gcg gtt gcc gcc ttt ttt tgt atc cgc aca gta 1632  
 Leu Ala Leu Ala Trp Ala Val Ala Ala Phe Phe Cys Ile Arg Thr Val  
 530 535 540

tct cgt gaa gtc tag  
Ser Arg Glu Val  
545

1647

<210> 4  
<211> 548  
<212> PRT  
<213> *Neisseria meningitidis*

<400> 4  
Met Lys Gln Asn Val Met Phe Leu Ile Leu Gly Arg Asn Phe Leu Lys  
1 5 10 15  
Ile Ile Leu Cys Phe Ser Phe Phe Val Pro Lys Phe Ala Leu Ala Ser  
20 25 30  
Val Asn Val Pro Gly Lys Phe Asp Arg Val Glu Val Tyr Asp Asp Gly  
35 40 45  
Arg Tyr Leu Gly Ile Arg Gly Ser Asp Asp Lys Arg Arg Arg Ile Trp  
50 55 60  
Lys Gly Val Phe Asp Arg Glu Ser Gly Arg Tyr Leu Thr Ser Glu Ala  
65 70 75 80  
Gln Asp Leu Lys Val Arg His Val Ser Thr Gly Ala Ser Ser Thr Gly  
85 90 95  
Lys Val Ser Ser Val Val Ser Ser Ser Val Ser Arg Ala Gly Val Leu  
100 105 110  
Ala Gly Val Gly Lys Leu Ala Arg Leu Gly Ala Lys Leu Ser Thr Arg  
115 120 125  
Ala Val Pro Tyr Val Gly Thr Ala Leu Leu Ala His Asp Val Tyr Glu  
130 135 140  
Thr Phe Lys Glu Asp Ile Gln Ala Gln Gly Tyr Gln Tyr Asp Pro Glu  
145 150 155 160  
Thr Asp Lys Phe Val Lys Gly Tyr Glu Tyr Ser Asn Cys Leu Trp Tyr  
165 170 175  
Glu Asp Lys Arg Arg Ile Asn Arg Thr Tyr Gly Cys Tyr Gly Val Asp  
180 185 190  
Ser Ser Ile Met Arg Leu Met Ser Asp Asp Ser Arg Phe Pro Glu Val

195                      200                      205  
 Lys Glu Leu Met Glu Ser Gln Met Tyr Arg Leu Ala Arg Pro Phe Trp  
 210                      215                      220  
 Asn Trp His Lys Glu Glu Leu Asn Lys Leu Ser Ser Leu Asp Trp Asn  
 225                      230                      235                      240  
 Asn Phe Val Leu Asn Arg Cys Thr Phe Asn Trp Asn Gly Gly Asp Cys  
 245                      250                      255  
 Leu Val Asn Lys Gly Asp Asp Phe Arg Asn Gly Ala Asp Phe Ser Leu  
 260                      265                      270  
 Ile Arg Asn Ser Lys Tyr Lys Glu Glu Met Asp Ala Lys Lys Leu Glu  
 275                      280                      285  
 Glu Ile Leu Ser Leu Lys Val Asp Ala Asn Pro Asp Lys Tyr Ile Lys  
 290                      295                      300  
 Glu Thr Gly Tyr Pro Gly Tyr Ser Glu Lys Val Glu Val Ala Pro Gly  
 305                      310                      315                      320  
 Thr Lys Val Asn Met Gly Pro Val Thr Asp Arg Asn Gly Asn Pro Val  
 325                      330                      335  
 Gln Val Val Ala Thr Phe Gly Arg Asp Ser Gln Gly Asn Thr Thr Val  
 340                      345                      350  
 Asp Val Gln Val Ile Pro Arg Pro Asp Leu Thr Pro Gly Ser Ala Glu  
 355                      360                      365  
 Ala Pro Asn Ala Gln Pro Leu Pro Glu Val Ser Pro Ala Glu Asn Pro  
 370                      375                      380  
 Ala Asn Asn Pro Asn Pro Asn Glu Asn Pro Gly Thr Ser Pro Asn Pro  
 385                      390                      395                      400  
 Glu Pro Asp Pro Asp Leu Asn Pro Asp Ala Asn Pro Asp Thr Asp Gly  
 405                      410                      415  
 Gln Pro Gly Thr Arg Pro Asp Ser Pro Ala Val Pro Gly Arg Thr Asn  
 420                      425                      430  
 Gly Arg Asp Gly Lys Asp Gly Lys Asp Gly Lys Asp Gly Gly Leu Leu  
 435                      440                      445  
 Cys Lys Phe Phe Pro Asp Ile Leu Ala Cys Asp Arg Leu Pro Glu Ser

450		455		460
Asn Pro Ala Glu Asp Leu Asn Leu Pro Ser Glu Thr Val Asn Val Glu				
465		470		475 480
Phe Gln Lys Ser Gly Ile Phe Gln Asp Ser Ala Gln Cys Pro Ala Pro				
	485		490	495
Val Thr Phe Thr Val Thr Val Leu Asp Ser Ser Arg Gln Phe Ala Phe				
	500		505	510
Ser Phe Glu Asn Ala Cys Thr Ile Ala Glu Arg Leu Arg Tyr Met Leu				
	515		520	525
Leu Ala Leu Ala Trp Ala Val Ala Ala Phe Phe Cys Ile Arg Thr Val				
	530		535	540
Ser Arg Glu Val				
545				